We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Hologic

Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App





Hologic Unveils Groundbreaking AI Research for Breast Cancer Detection

By MedImaging International staff writers
Posted on 01 Mar 2024
Image: The Genius AI Detection technology is commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024 (Photo courtesy of Hologic)
Image: The Genius AI Detection technology is commercially available in the U.S., with plans for rollout in Europe, Canada and Asia by the end of 2024 (Photo courtesy of Hologic)

Hologic, Inc. (Marlborough, MA, USA) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology (ECR) in Vienna, Austria from February 28 to March 2.

The pioneer behind 3D mammography, Hologic is presenting new data that showcase how next-generation deep-learning solutions can assist with breast cancer detection and improve workflow for radiologists. The research shows that Hologic’s Genius AI Detection solution has an exceptional ability to correctly match pairs of Regions of Interest (ROIs) in different views. In addition, Hologic is also presenting research highlighting how the Genius AI Detection algorithm can help radiologists identify potential cancers on mammograms previously interpreted as normal.

In a third study, Hologic is presenting research that demonstrates its deep learning-based AI algorithm can help significantly enhance performance, surpassing traditional machine learning Computer-Aided Detection (CAD) algorithms in specificity and overall effectiveness. In addition, Hologic and Bayer will be co-sponsoring a contrast-enhanced mammography (CEM) symposium, facilitated by globally recognized breast imaging radiologists. The symposium is designed to provide radiologists with an understanding of how CEM can be effectively implemented into their daily practice.

“These data reveal how AI can help us correlate ROIs in a way that we have never seen before, which underscores that deep-learning technology can supplement our workflow as radiologists and help us provide better patient care,” said esteemed breast imaging specialist and study author Dr. Sarah M. Friedewald, Associate Professor of Radiology and Chief of Breast Imaging at Northwestern Memorial Hospital. “Beyond its impact on our daily practices, these data emphasize the transformative potential AI has to drive improvements across the breast health spectrum. I’m looking forward to sharing this information with my colleagues from around the globe at ECR.”

“Research and education are central tenets of Hologic’s innovation, to support radiologists in achieving better patient outcomes,” added Tanja Brycker, Vice President, Strategic Development, Breast & Skeletal Health and Gynecological Surgical Solutions at Hologic. “We’re excited to present groundbreaking research at ECR and to continue our collaboration with Bayer on contrast-enhanced mammography. By offering our customers the opportunity to engage with world-renowned experts and explore our latest technology, we are ensuring they feel confident in their patient care procedures and decisions.”

Related Links:
Hologic, Inc. 

Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Digital X-Ray Detector Panel
Acuity G4
Ultrasound Table
Women’s Ultrasound EA Table
Digital Radiography System
DR-300

Channels

General/Advanced Imaging

view channel
Image: The study developed a marker based on the analysis of routine CT scans of gastric cancer patients treated at UNICAMP. Higher radiodensity values for adipose tissue are linked to a worse prognosis. In contrast, higher values for muscle are linked to a more favorable outcome (Photo courtesy of FCM-UNICAMP)

CT-Derived Biomarker Predicts Outcomes in Gastric Cancer

Gastric cancer, also known as stomach cancer, is the fifth most common malignancy worldwide and often shows heterogeneous outcomes even within the same stage. Prognostic estimates typically rely on tumor-centric... Read more

Industry News

view channel
Image: MIM KineticID is 510(k)-pending software for dynamic PET imaging and kinetic modeling, enabling time-based radiotracer analysis for clinical and research decisions (Photo courtesy of GE Healthcare)

GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026

Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.